Figure 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

A, INCAGN01876 mean (±SE) concentration–time profiles after the first dose and at steady state. B, Relationship between serum concentrations of INCAGN01876 and GITR receptor occupancy. C, Percentage of INCAGN01876 receptor occupancy vs. time. The average receptor occupancy per cohort is depicted (± SD). PK analysis includes patients with ADA-negative status at the respective visit; first visit/steady state: 0.03 mg/kg, n = 4/n = 0; 0.1 mg/kg, n = 4/n = 0; 0.3 mg/kg, n = 3/n = 1; 1 mg/kg, n = 3/n = 1; 3 mg/kg, n = 15/n = 5; 5 mg/kg, n = 16/n = 5; 10 mg/kg, n = 14/n = 4; 20 mg/kg, n = 3/n = 0; 300 mg, n = 21/n = 7; and 400 mg, n = 9/n = 3. RO, receptor occupancy.